Freatment of Malignant Hyperthermia without Dantrolene in a 14-year-old Boy  

作　　者：Shu-Ting Liu Li-Fei Liu Shou-Yong Wang 

机构地区：[1]Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China

出　　处：《Chinese Medical Journal》2017年第6期755-756,共2页中华医学杂志（英文版）

摘　　要：To the Editor： Malignant hyperthermia （MH） is a rare but potentially fatal, inherited skeletal muscle disorder that is mostly induced by the ingestion of the depolarizing relaxant, i.e., succinylcholine or volatile anestheticsY1 Its incidence is reportedly 1/5000 to 1/100,000 in general anesthesia patients, and children seem to be more susceptible than adults.121 According to MH treatment guidelines of the Malignant Hyperthermia Association of the United States （MHAUS） and European Malignant Hyperthermia Group （EMHG）, dantrolene should be administered as soon as possible in suspected case.To the Editor： Malignant hyperthermia （MH） is a rare but potentially fatal, inherited skeletal muscle disorder that is mostly induced by the ingestion of the depolarizing relaxant, i.e., succinylcholine or volatile anestheticsY1 Its incidence is reportedly 1/5000 to 1/100,000 in general anesthesia patients, and children seem to be more susceptible than adults.121 According to MH treatment guidelines of the Malignant Hyperthermia Association of the United States （MHAUS） and European Malignant Hyperthermia Group （EMHG）, dantrolene should be administered as soon as possible in suspected case.

分 类 号：R720.597[医药卫生—急诊医学]